引用本文: 紀(jì)宗正,張焱. 胰體尾癌的綜合治療. 中國普外基礎(chǔ)與臨床雜志, 2011, 18(1): 3-5. doi: 復(fù)制
1. | Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74108. |
2. | Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer [J]. Cancer, 1995, 76(9): 16711677. |
3. | Baumel H, Huguier M, Manderscheid JC, et al. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery [J]. Br J Surg, 1994, 81(1): 102107. |
4. | Fabre JM, Houry S, Manderscheid JC, et al. Surgery for leftsided pancreatic cancer [J]. Br J Surg, 1996, 83(8): 10651070. |
5. | Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas [J]. Ann Surg, 1996, 223(5): 506512. |
6. | Shoup M, Conlon KC, Klimstra D, et al. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? [J]. J Gastrointest Surg, 2003, 7(8): 946952. |
7. | Shimada K, Sakamoto Y, Sano T, et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail [J]. Surgery, 2006, 139(3): 288295. |
8. | Warshaw AL. Distal pancreatectomy with preservation of the spleen [J]. J Hepatobiliary Pancreat Sci, 2010, 17(6): 808812. |
9. | Christein JD, Kendrick ML, Iqbal CW, et al. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas [J]. J Gastrointest Surg, 2005, 9(7): 922927. |
10. | 趙玉沛. 胰腺病學(xué) [M]. 北京: 人民衛(wèi)生出版社, 2007: 526528. |
11. | Kondo S, Katoh H, Hirano S, et al. Results of radical distal pancreatectomy with en bloc resection of the celiac artery for locally advanced cancer of the pancreatic body [J]. Langenbecks Arch Surg, 2003, 388(2): 101106. |
12. | Hayashibe A, Kameyama M, Shinbo M, et al. Clinical results on intraarterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer [J]. Ann Surg Oncol, 2007, 14(1): 190194. |
13. | Ji Z, Wang Y, Chen X, et al. Peripancreatic artery ligation and artery infusion chemotherapy for advanced pancreatic carcinoma [J]. Chin Med J (Engl), 2003, 116(1): 8992. |
14. | Mohiuddin M, Rosato F, Barbot D, et al. Longterm results of combined modality treatment with I125 implantation for carcinoma of the pancreas [J]. Int J Radiat Oncol Biol Phys, 1992, 23(2): 305311. |
15. | Nori D, Merimsky O, Osian AD, et al. Palladium103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase ⅠⅡ study [J]. J Surg Oncol, 1996, 61(4): 300305. |
16. | Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer [J]. Cancer, 1987, 59(12): 20062010. |
17. | Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent resection of pancreatic cancer: a randomized controlled trial [J]. JAMA, 2007, 297(3): 267277. |
18. | National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: pancreatic adenocarcinoma V.2.2010 [EB/OL]. http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf. |
19. | Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997, 15(6): 24032413. |
20. | Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase Ⅲ trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer [J]. J Clin Oncol, 2006, 24(24): 39463952. |
21. | Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival [J]. Ann Surg Oncol, 2006, 13(9): 12011208. |
22. | Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection [J]. Arch Surg, 1985, 120(8): 899903. |
23. | Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase Ⅲ trial of the EORTC gastrointestinal tract cancer cooperative group [J]. Ann Surg, 1999, 230(6): 776784. |
24. | Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial [J]. Lancet, 2001, 358(9293): 15761585. |
25. | Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6 000 rads) radiation alone, moderate dose radiation (4 000 rads+5fluorouracil), and high dose radiation+5fluorouracil: The Gastrointestinal Tumor Study Group [J]. Cancer, 1981, 48(8): 17051710. |
26. | Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol, 2007, 25(15): 19601966. |
27. | Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase Ⅲ trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer [J]. J Clin Oncol, 2009, 27(13): 22312237. |
- 1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74108.
- 2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer [J]. Cancer, 1995, 76(9): 16711677.
- 3. Baumel H, Huguier M, Manderscheid JC, et al. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery [J]. Br J Surg, 1994, 81(1): 102107.
- 4. Fabre JM, Houry S, Manderscheid JC, et al. Surgery for leftsided pancreatic cancer [J]. Br J Surg, 1996, 83(8): 10651070.
- 5. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas [J]. Ann Surg, 1996, 223(5): 506512.
- 6. Shoup M, Conlon KC, Klimstra D, et al. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? [J]. J Gastrointest Surg, 2003, 7(8): 946952.
- 7. Shimada K, Sakamoto Y, Sano T, et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail [J]. Surgery, 2006, 139(3): 288295.
- 8. Warshaw AL. Distal pancreatectomy with preservation of the spleen [J]. J Hepatobiliary Pancreat Sci, 2010, 17(6): 808812.
- 9. Christein JD, Kendrick ML, Iqbal CW, et al. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas [J]. J Gastrointest Surg, 2005, 9(7): 922927.
- 10. 趙玉沛. 胰腺病學(xué) [M]. 北京: 人民衛(wèi)生出版社, 2007: 526528.
- 11. Kondo S, Katoh H, Hirano S, et al. Results of radical distal pancreatectomy with en bloc resection of the celiac artery for locally advanced cancer of the pancreatic body [J]. Langenbecks Arch Surg, 2003, 388(2): 101106.
- 12. Hayashibe A, Kameyama M, Shinbo M, et al. Clinical results on intraarterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer [J]. Ann Surg Oncol, 2007, 14(1): 190194.
- 13. Ji Z, Wang Y, Chen X, et al. Peripancreatic artery ligation and artery infusion chemotherapy for advanced pancreatic carcinoma [J]. Chin Med J (Engl), 2003, 116(1): 8992.
- 14. Mohiuddin M, Rosato F, Barbot D, et al. Longterm results of combined modality treatment with I125 implantation for carcinoma of the pancreas [J]. Int J Radiat Oncol Biol Phys, 1992, 23(2): 305311.
- 15. Nori D, Merimsky O, Osian AD, et al. Palladium103: a new radioactive source in the treatment of unresectable carcinoma of the pancreas: a phase ⅠⅡ study [J]. J Surg Oncol, 1996, 61(4): 300305.
- 16. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer [J]. Cancer, 1987, 59(12): 20062010.
- 17. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent resection of pancreatic cancer: a randomized controlled trial [J]. JAMA, 2007, 297(3): 267277.
- 18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: pancreatic adenocarcinoma V.2.2010 [EB/OL]. http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf.
- 19. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997, 15(6): 24032413.
- 20. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase Ⅲ trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer [J]. J Clin Oncol, 2006, 24(24): 39463952.
- 21. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival [J]. Ann Surg Oncol, 2006, 13(9): 12011208.
- 22. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection [J]. Arch Surg, 1985, 120(8): 899903.
- 23. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase Ⅲ trial of the EORTC gastrointestinal tract cancer cooperative group [J]. Ann Surg, 1999, 230(6): 776784.
- 24. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial [J]. Lancet, 2001, 358(9293): 15761585.
- 25. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6 000 rads) radiation alone, moderate dose radiation (4 000 rads+5fluorouracil), and high dose radiation+5fluorouracil: The Gastrointestinal Tumor Study Group [J]. Cancer, 1981, 48(8): 17051710.
- 26. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol, 2007, 25(15): 19601966.
- 27. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase Ⅲ trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer [J]. J Clin Oncol, 2009, 27(13): 22312237.